The Women's Screening and Self-Testing Program (PROMETA) Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (HIV) care and treatment services. The primary outcome of interest is the number of women screened and the proportion of screen-positive women undergoing treatment. Secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across Mozambique.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 25-49 lat
- •Korzystanie z poradni HIV
- •Nieciążowe
- •Posiadanie szyjki macicy
✗ Disqualifies
- •Zaburzenia fizyczne lub psychiczne uniemożliwiające udział w badaniu
- •Ciąża lub okres poniżej 6 tygodni po porodzie
- •Usunięcie macicy wraz z szyjką
Simplified criteria — AI translation
Trial details
- Minimum age
- 25 Years
- Maximum age
- 49 Years
- Last updated (source)
- July 20, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
University Eduardo Mondlane (UEM)
Maputo, Mozambique
Trial contact
Kathryn Kampa, MPH
Harriett Myers, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.